文献速递功能神经外科

双侧双靶点脑深部电刺激治疗帕金森病的初步临床结局:Summit RC+S 试验

Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S.
PubMed 文献 · Neurosurgery · 2022-04-07

该初步试验(n=3)植入双侧丘脑底核(STN)与苍白球(GP)脑深部电刺激(DBS)电极并连接双向植入式脉冲发生器(Medtronic Summit RC+S),1年结果显示联合DBS改善帕金森病症状控制,允许左旋多巴剂量减少>80%,多电极激活时关期运动UPDRS降幅大于STN或GP单独刺激,2例发生不良事件。

要点

  • 联合STN与GP的DBS改善帕金森病症状控制,允许左旋多巴剂量减少>80%。
  • 多电极激活时关期运动UPDRS平均差值-18.2(范围-25.5至-12.5),大于STN单独(-12.8,范围-20.5至0)或GP单独(-9,范围-11.5至-4.5)。
  • 联合DBS在5/6半球中降低STN beta振荡的幅度大于任一靶点单独刺激。

核心结论

  • 在该初步队列中,帕金森病患者偏好联合DBS刺激;未来研究将进一步明确生物标志物与控制策略以评估自适应DBS的疗效。

研究设计与样本

  • 观察性初步试验(n=3),植入双侧STN与GP DBS电极并连接双向植入式脉冲发生器(Medtronic Summit RC+S;NCT03815656,IDE编号G180280),评估3例患者初始1年结局。

主要发现

  • 联合DBS改善帕金森病症状控制,允许左旋多巴剂量减少>80%。
  • 多电极激活时关期运动UPDRS平均差值-18.2(范围-25.5至-12.5),STN单独为-12.8(范围-20.5至0),GP单独为-9(范围-11.5至-4.5)。
  • 联合DBS在5/6半球中降低STN beta振荡的幅度大于任一靶点单独刺激。
  • 2例患者发生不良事件,包括小皮质出血和术后24小时癫痫(自行缓解),以及术后2个月需修正的延伸导线瘢痕。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deep brain stimulation (DBS) is an effective therapy in advanced Parkinson disease (PD). Although both subthalamic nucleus (STN) and globus pallidus (GP) DBS show equivalent efficacy in PD, combined stimulation may demonstrate synergism. OBJECTIVE: To evaluate the clinical benefit of stimulating a combination of STN and GP DBS leads and to demonstrate biomarker discovery for adaptive DBS therapy in an observational study. METHODS: We performed a pilot trial (n = 3) of implanting bilateral STN and GP DBS leads, connected to a bidirectional implantable pulse generator (Medtronic Summit RC + S; NCT03815656, IDE No. G180280). Initial 1-year outcome in 3 patients included Unified PD Rating Scale on and off medications, medication dosage, Hauser diary, and recorded beta frequency spectral power. RESULTS: Combined DBS improved PD symptom control, allowing >80% levodopa medication reduction. There was a greater decrease in off-medication motor Unified PD Rating Scale with multiple electrodes activated (mean difference from off stimulation off medications -18.2, range -25.5 to -12.5) than either STN (-12.8, range -20.5 to 0) or GP alone (-9, range -11.5 to -4.5). Combined DBS resulted in a greater reduction of beta oscillations in STN in 5/6 hemispheres than either site alone. Adverse events occurred in 2 patients, including a small cortical hemorrhage and seizure at 24 hours postoperatively, which resolved spontaneously, and extension wire scarring requiring revision at 2 months postoperatively. CONCLUSION: Patients with PD preferred combined DBS stimulation in this preliminary cohort. Future studies will address efficacy of adaptive DBS as we further define biomarkers and control policy.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Mitchell KT, Schmidt SL, Cooney JW, et al. Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S. Neurosurgery. 2022. PMID: 35383660. doi:10.1227/neu.0000000000001957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。